A Phase 1, Open-label Study In Healthy Subjects To Evaluate The Pharmacokinetics Of Pf-06882961 Following Single Oral Administration Of Immediate Release Tablets And An Immediate Release Oral Solution In The Fed State, And Controlled Release Tablets In The Fed And Fasted States

Pfizer1 个研究点分布在 1 个国家目标入组 12 人开始时间: 2018年4月30日最近更新: 2018年7月30日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Pfizer
入组人数: 12
试验地点: 1
主要终点: Maximum Observed Plasma Concentration (Cmax) for PF-06882961

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Basic Science
盲法: None

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive
•Body mass index (BMI) within 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)
•Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study

排除标准

•Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal (including pancreatitis), cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
•Any condition possibly affecting drug absorption (eg, gastrectomy).
•A positive urine drug test.
•History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects within 6 months before screening.
•Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).
•Subjects who have previously participated in prior studies with PF 06882961 as the investigational product.
•Screening supine BP>=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of supine rest.
•Screening supine 12 lead ECG demonstrating a QTc interval >450 msec or a QRS interval >120 msec.
•Aspartate aminotransferase (AST) level >= 1.25 × upper limit of normal (ULN);
•Alanine aminotransferase (ALT) level >= 1.25 × ULN;
•Total bilirubin level >=1.5 × ULN;
•TSH > ULN;
•HbA1c >=6.5%.
•Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for at least 28 days after the last dose of investigational product.
•Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product
•Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
•History of sensitivity to heparin or heparin induced thrombocytopenia.
•History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb).
•Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), or subjects with suspected MTC per the investigator's judgement.
•Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of the protocol.
•Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
•Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study

研究组 & 干预措施

PF-06882961

Experimental

干预措施: PF-06882961 Immediate Release Tablet (Drug)

PF-06882961

Experimental

干预措施: PF-06882961 Controlled Release Tablet (long) (Drug)

PF-06882961

Experimental

干预措施: PF-06882961 Controlled Release Tablet (short) (Drug)

PF-06882961

Experimental

干预措施: PF-06882961 Immediate Release Solution (Drug)